Paper Details

  1. Home
  2. Paper Details

Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.

Author: Al-SamkariH

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Avatrombopag is a new drug that stimulates the production of platelets. It is approved by the FDA for treating periprocedural thrombocytopenia in patients with chronic liver disease. It is also being studied for other uses, such as treating immune thrombocytopenia and chemotherapy-induced thrombocytopenia.
Paper Details　
Original Abstract of the Article :
Avatrombopag maleate (Doptelet; Dova Pharmaceuticals) is an oral, small-molecule second-generation thrombopoietin (TPO) receptor agonist under development for the treatment of thrombocytopenia. Recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of periprocedural throm...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1358/dot.2018.54.11.2899441

データ提供：米国国立医学図書館（NLM）

Avatrombopag: A New Oasis in the Desert of Thrombocytopenia Treatment

Thrombocytopenia, a condition characterized by a low platelet count, can be a challenging problem, especially in patients with chronic liver disease. This research delves into the potential of avatrombopag maleate, a novel oral medication, as a treatment for periprocedural thrombocytopenia, a condition that often arises during medical procedures. This study explores the drug's preclinical and clinical pharmacology, its safety profile, and its potential for treating various forms of thrombocytopenia.

Avatrombopag: A Promising Oasis for Thrombocytopenia

Avatrombopag maleate has emerged as a promising new treatment for periprocedural thrombocytopenia in patients with chronic liver disease. The study highlights its potential for treating other types of thrombocytopenia, as well, offering a glimmer of hope for patients struggling with this condition.

Navigating the Dunes of Thrombocytopenia Treatment

This research provides a valuable roadmap for clinicians navigating the treatment of thrombocytopenia, particularly in patients with chronic liver disease. While further research is needed to fully understand the drug's long-term effects and potential interactions with other medications, avatrombopag maleate offers a promising new option for patients seeking relief from this challenging condition.

Dr.Camel's Conclusion

This study offers a promising glimpse into the potential of avatrombopag maleate as a new treatment for thrombocytopenia. With its proven efficacy and favorable safety profile, this drug could provide a much-needed oasis for patients battling this condition, particularly those with chronic liver disease.

Date :
  1. Date Completed 2019-03-06
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

30539164

DOI: Digital Object Identifier

10.1358/dot.2018.54.11.2899441

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.